Skip to main navigation Skip to search Skip to main content

Liver enzyme alterations during pregnancy in IBD are not attributable to disease activity or medication

  • Dianne G Bouwknegt
  • , Hylke C Donker
  • , Bram van Es
  • , Gerard Dijkstra
  • , Willemijn A van Dop
  • , Jelmer R Prins
  • , Tjebbe Tauber
  • , C Janneke van der Woude
  • , Marijn C Visschedijk*
  • ,
  • *Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Downloads (Pure)

Abstract

BACKGROUND: Inflammatory bowel disease (IBD) is often diagnosed during reproductive age, requiring adequate management during pregnancy. Physiological changes during pregnancy affect liver enzymes, complicating interpretation in a population prone to liver test abnormalities. This study aims to investigate liver enzyme trends throughout pregnancy in women with IBD.

METHODS: A retrospective cohort study was conducted in three Dutch university hospitals. Pregnant women with IBD were included; liver enzyme levels were analyzed throughout pregnancy using Bayesian modeling. The association between liver enzymes and IBD disease activity, medication, pregnancy and adverse pregnancy outcomes was assessed, with estimated marginal means (EMMs) reported across trimesters and clinical subgroups.

RESULTS: Liver enzyme levels exhibited significant trimester-specific variations in pregnant individuals with IBD. Levels of aminotransferases, γ-glutamyl transferase (γGT) and bilirubin generally declined, particularly in the second trimester, whereas alkaline phosphatase (ALP) levels increased markedly in the third trimester, mirroring physiological changes observed in healthy pregnancies. Adverse pregnancy outcomes were not associated with differences in liver enzyme levels. Several medications - particularly ustekinumab, vedolizumab, thiopurines, corticosteroids and amino salicylates - were associated with liver enzyme values or interacted with pregnancy, modulating the direction or magnitude of change. However, these effects were generally modest and remained within reference values.

CONCLUSIONS: In pregnant women with IBD, changes in liver enzyme levels reflect physiological gestational adaptations rather than pharmacologic effects. Although medication-specific interactions were detected, their clinical significance appears limited. Marked elevations in liver enzymes during pregnancy cannot routinely be attributed to IBD activity or medication and warrant urgent analysis.

Original languageEnglish
Pages (from-to)317-328
Number of pages12
JournalScandinavian Journal of Gastroenterology
Volume61
Issue number3
Early online date16 Jan 2026
DOIs
Publication statusPublished - Mar 2026

Fingerprint

Dive into the research topics of 'Liver enzyme alterations during pregnancy in IBD are not attributable to disease activity or medication'. Together they form a unique fingerprint.

Cite this